Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
MYH6 CRISPR/Cas9 KO Plasmid (h): sc-400351
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- MYH6 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the MYH6 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MYH6 CRISPR/Cas9 KO Plasmid (h) | sc-400351 | 20 µg | $397.00 |
Overview
MYH6 encodes the alpha heavy chain of cardiac myosin II, a principal motor protein of the sarcomere that powers actin-dependent contractile force generation in striated muscle. Through ATPase-driven cross-bridge cycling, MYH6 contributes to myofibril organization, calcium-sensitive contractility, and cardiac muscle development, integrating with pathways that regulate sarcomere assembly and mechanotransduction. Altered MYH6 expression or sequence variation is associated with inherited cardiomyopathies and congenital heart disease phenotypes, reflecting its central role in myocardial function. As a tissue-enriched contractile gene, MYH6 is widely used to interrogate cardiomyocyte maturation, stress responses, and structural remodeling in cellular and genetic model systems.
MYH6 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the MYH6 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the MYH6 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the MYH6 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish MYH6 protein expression.
This CRISPR knockout system enables efficient generation of MYH6-deficient cell models for investigation of MYH6 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting MYH6 exon(s) critical for MYH6 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple MYH6 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by MYH6 CRISPR/Cas9 KO Plasmid (h) and MYH6 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the MYH6 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by MYH6 HDR Plasmid (h) and MYH6 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by MYH6 homology arms to support homology-directed repair at defined MYH6 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.